Chimeric Therapeutics (ASX:CHM) said that the University of Chicago Medicine will enroll patients in its multi-center phase one/two clinical trial for its anti-CDH17 chimeric antigen receptor T-cell therapy, according to a Monday Australian bourse filing.
The trial is a two-stage study to determine a recommended phase two dose of CHM CDH17 and evaluate its safety and objective response rate in patients with advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumors.
CHM CDH17 is a CAR T-cell therapy, a type of immunotherapy, that targets CDH17, a cancer target associated with poor prognosis and metastases in the most common gastrointestinal tumors, the filing said.
The first phase of the study is expected to enroll 15 patients.
Its shares rose 14% on market close.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。